According to USA Today, Zantac has been prescribed more than 15 million times a year for over a decade.
Zantac is a brand-name medication that was commonly used to treat conditions related to excess stomach acid, such as heartburn, acid reflux (GERD), and stomach ulcers. Its active ingredient, ranitidine, works by reducing the amount of acid the stomach produces. Unfortunately, with enough exposure to this medication, it can cause cancer.
If this happens to you or a loved one, you may have a case for legal action, according to a North Carolina Zantac lawyer. You may file personal injury lawsuits against manufacturers and seek compensation for medical expenses, lost wages, and pain and suffering.
Learn how a Zantac lawsuit becomes a personal injury case and what it means for your legal rights.
The Legal Theory: Products Liability and Failure to Warn
The Zantac cases are not ordinary negligence claims but product liability matters. The doctrine that a manufacturer is strictly liable for injury caused by his product, no matter in the least that the victim need not prove the manufacturer's unreasonable conduct under the traditional negligence doctrine, is still followed regardless of modifications made by courts and law reformers in some states.
The Zantac cases currently argue that manufacturers failed to provide warning information because they understood that ranitidine, which exists as the primary Zantac component, functions as an unstable molecule that transforms into NDMA under specific environmental circumstances.
The International Agency for Research on Cancer considers NDMA to be a likely human carcinogen. The FDA disclosed in its market withdrawal announcement of April 2020 that ranitidine products develop increasing levels of NDMA through the combination of time and high storage temperatures until they exceed the agency's acceptable daily intake limit.
Another theory in many complaints is that there is a foundation design defect, specifically that ranitidine is inherently defective in its chemical structure and, under certain conditions, will create NDMA. The product is unreasonably unsafe, regardless of anyone's actions.
The Core Legal Challenge: Causation
The core debate in the Zantac cases has never been whether ranitidine produces NDMA or not, but actually, whether the levels of NDMA generated by ranitidine are enough to bring about cancer in humans. This causation issue has been the pivotal hurdle in every court proceeding since the beginning.
In December 2022, U.S. District Judge Robin Rosenberg dismissed all federal cases consolidated in the Drug Substances Multidistrict Litigation in the Southern District of Florida, concluding that the methods used by the plaintiffs' general causation experts were methodologically untrustworthy under the Daubert v. Merrell Dow Pharmaceuticals, Inc. standards.
The judge found that the implementers of the plaintiffs' supporting expert opinions had not been reeled into creating a direct, scientifically reliable link between NDMA, sourced exclusively from ranitidine, and human cancer. With this judgment in place, the federal MDL ended up falling apart. The plaintiffs lodged an appeal with the United States Court of Appeals for the Eleventh Circuit and were granted oral argument on October 10, 2025, with the judgment still pending as of April 2026.
The state court has further complicated the situation. The Delaware Superior Court rejected Zantac's attempts to exclude the expert opinions for tens of thousands of cases remaining against it in May 2024, defeating the post-Daubert challenge that had recently succeeded in federal court.
On July 10, 2025, the Delaware Supreme Court reversed the ruling in In re Zantac (Ranitidine) Litigation, No. 255, 2024, determining that the plaintiffs' experts did not testify about increased N-nitrosodimethylamine (NDMA) levels formed catalytically from ranitidine compared to the levels of NDMA that normally form from ranitidine and that their reports were based on literature.
A skilled attorney can have a big impact on your case. If you are suffering this injustice, consulting a lawyer will help you have a strong legal representation and hold the negligent party accountable for the harm you suffered, according to personal injury lawyer Michael W. Czack Esq.
Settlements and Remaining Litigation
Major settlements have already been accomplished despite court outcomes. GSK had informed about a settlement of up to $2.2 billion for tens of thousands of state court plaintiffs in October 2024 and was optimistic that the settlement would be carried out by mid-2025.
Sanofi has settled more than 10,000 cases and has paid between $200 million and $250 million in 2024. Pfizer also settled more than 10,000 cases. Boehringer Ingelheim has continued to litigate rather than settle.
The settlements are not admissions of liability. Each settling manufacturer has maintained that the science does not indicate that ranitidine causes cancer. The settlements constitute a business decision to end unresolved matters, rather than a judicial or regulatory conclusion stating that any liability exists.
Though many cases are ongoing in various state courts, primarily in Delaware, California, and Illinois, with a federal docket that could possibly grow or shrink depending on the Eleventh Circuit appeal, as of April 2026, most litigation has been tentatively resolved.
Who May Have Claims and What to Consider
Many people who used Zantac and later developed cancer cases related to the use of ranitidine and its generic equivalents have filed cases against the tablets on a wide-ranging scale and for various cancer types. The majority of litigation appears to focus on bladder cancer, which has the strongest claimed association in various expert reports for plaintiffs.
The key question is when the limitation period begins. Several U.S. states would say that the timer starts to run when a potential claimant knows or should have known of the injury and its cause. Several perspectives state that the limitation period runs from the date of the incident.
In 2020, a public announcement from the FDA indicated that statutes of limitations may seem to have already started running, thus signifying deadlines for anyone seeking to file a claim. The FDA's announcement, and the spate of excellent coverage since that time, should reinforce the wisdom of consulting counsel immediately.
Those thinking about pursuing a case centered on Zantac must be mindful that the legal environment has undergone radical changes since 2022. The dismissal of the federal MDL, the ruling in the Delaware Supreme Court, and the lack of a major plaintiff verdict in any concluded Zantac cancer cases go to demonstrate the very genuine scientific and legal challenges posed by proof of causation.
People who want to become plaintiffs should meet with an experienced pharmaceutical attorney to discuss their current legal situation to help them assess whether or not their case has merit.
